BIOXYTRAN INC (BIXT)
BIXT moved a median of 0.00% 30 minutes after news, and +0.13% by the close. How BIXT actually reacts to news — the realized, point-in-time move the market made, measured across 125 labeled events over the last three years with zero look-ahead.
BIXT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 17% | 98 |
| 30-min | 0.00% | 22% | 108 |
| 60-min | 0.00% | 36% | 112 |
| to close | +0.13% | 50% | 122 |
| Middle 50% of BIXT reactions | -3.16% to 0.00% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 125 |
Half of all BIOXYTRAN INC news events land between -3.16% and +0.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when BIXT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BIXT's baseline. Nothing else.
Recent BIXT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 10-Q BIOXYTRAN, INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +24.76% | |
| Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence | Press release | GlobeNewswire | +0.00% | +8.30% | |
| Form 8-K BIOXYTRAN, INC For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +8.30% | |
| Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs | Press release | GlobeNewswire | -7.08% | -2.65% | |
| Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25 | Press release | GlobeNewswire | — | — | |
| Form 10-Q BIOXYTRAN, INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | +0.00% | |
| Form 10-K BIOXYTRAN, INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | — | |
| Form NT 10-K BIOXYTRAN, INC For: Dec 31 | SEC filing · Form NT | SEC EDGAR | +0.00% | -3.99% | |
| Form 8-K BIOXYTRAN, INC For: Mar 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +7.44% | |
| Form 8-K BIOXYTRAN, INC For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +1.67% | -2.51% | |
| Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M | Press release | GlobeNewswire | — | +1.18% | |
| Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 | Press release | ACCESS Newswire | +0.00% | -6.67% | |
| Form 8-K BIOXYTRAN, INC For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -12.50% | |
| Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus | Press release | ACCESS Newswire | +0.00% | -2.14% | |
| Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement | Press release | ACCESS Newswire | +0.00% | -0.82% | |
| Form 8-K BIOXYTRAN, INC For: Feb 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.82% | |
| Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran | Press release | GlobeNewswire | -1.01% | +3.90% | |
| Form 8-K BIOXYTRAN, INC For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | -1.01% | +3.90% | |
| Bioxytran CEO David Platt, Ph.D. to Present at Noble Capital Markets' Emerging Growth Virtual Equity Conference | Press release | ACCESS Newswire | +5.88% | +18.82% | |
| Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics | Press release | GlobeNewswire | +0.00% | +21.38% | |
| Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline | Press release | ACCESS Newswire | — | +0.00% | |
| Form 8-K BIOXYTRAN, INC For: Dec 29 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +5.06% | |
| Form 8-K BIOXYTRAN, INC For: Dec 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.24% | |
| Form 10-Q BIOXYTRAN, INC For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -7.61% | |
| Bioxytran Announces Initiation of Coverage of its Stock by Independent Research | Press release | GlobeNewswire | — | — | |
| Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug | Press release | GlobeNewswire | +0.00% | +12.79% | |
| Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation | Press release | GlobeNewswire | +0.00% | +2.56% | |
| Form 10-Q BIOXYTRAN, INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.85% | -0.35% | |
| Bioxytran’s Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment | Press release | GlobeNewswire | +0.78% | -0.22% | |
| Bioxytran Secures a Source of GMP Quality Camel Hemoglobin | Press release | GlobeNewswire | -2.65% | -3.54% | |
| Bioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation That Measures Oxygenation Uptake During Strokes | Press release | GlobeNewswire | +5.80% | +6.03% | |
| Bioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge Submission | Press release | GlobeNewswire | +0.00% | +4.73% | |
| Form 10-Q BIOXYTRAN, INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | +0.00% | |
| Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M | Press release | GlobeNewswire | +9.36% | -0.71% | |
| Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements | Press release | GlobeNewswire | +0.65% | -4.57% | |
| Form 10-K BIOXYTRAN, INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +19.80% | |
| Form 8-K/A BIOXYTRAN, INC For: Oct 25 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +19.80% | |
| Form NT 10-K BIOXYTRAN, INC For: Dec 31 | SEC filing · Form NT | SEC EDGAR | +0.00% | +7.91% | |
| Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens | Press release | GlobeNewswire | -2.35% | -0.94% | |
| Bioxytran Develops a Groundbreaking Treatment to Combat Bird Flu in Egg Laying Chickens Potentially Saving Billions | Press release | GlobeNewswire | +3.12% | +37.27% | |
| Form EFFECT BIOXYTRAN, INC | SEC filing · Form EFFECT | SEC EDGAR | +2.50% | +7.38% | |
| Form S-1/A BIOXYTRAN, INC | SEC filing · Form S-1 | SEC EDGAR | +0.00% | -1.21% | |
| Form S-1/A BIOXYTRAN, INC | SEC filing · Form S-1 | SEC EDGAR | +0.00% | +0.69% | |
| Form DEL AM BIOXYTRAN, INC | SEC filing · Form DEL | SEC EDGAR | — | +0.00% | |
| Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development | Press release | GlobeNewswire | -3.30% | +4.95% | |
| Form 8-K BIOXYTRAN, INC For: Jan 15 | SEC filing · Form 8-K | SEC EDGAR | -3.30% | +4.95% | |
| Form S-1 BIOXYTRAN, INC | SEC filing · Form S-1 | SEC EDGAR | +17.88% | +0.27% | |
| Form 10-K/A BIOXYTRAN, INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | +5.50% | |
| Form 8-K BIOXYTRAN, INC For: Jan 13 | SEC filing · Form 8-K | SEC EDGAR | — | +5.50% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BIXT section they belong to.
Where else BIXT is measured.
BIXT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BIOXYTRAN INC's median reaction calculated?
Every labeled BIXT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 125 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 22% of BIXT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BIXT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.